.INVESTIGATION HIGHLIGHT.16 October 2024. In the NIAGARA hearing, the enhancement of perioperative durvalumab to basic therapy for muscle-invasive bladder cancer boosted event-free and also generally survival, marking a new treatment choice for this health condition.